pharmaphorum5d
FDA approves GSK's Blenrep for advanced multiple myeloma
The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...
Hosted on MSN8mon
GSK’s Blenrep combo therapy meets key goal in multiple myeloma trial
The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex. A pre-specified interim ...
pharmaphorum9d
Is GSK’s Blenrep heading for a renaissance?
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...
Hosted on MSN11mon
EU regulators recommend against renewing approval for GSK's Blenrep
EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (NYSE:GSK) blood cancer drug Blenrep. According to Reuters, a European Medicines Agency committee has ...